The future is in Biotechnology!
A leader in biotechnology based human therapeutic, with historical expertise in renal disease and cancer supportive care products.
Key ratio
-revenue increasing trend
-net income increase to 4.65 from 4.25
-eps 4.25 to 4.65[Like]
-total debt to equity ratio 15.09
-fcf reduced to 8417 in march from 10497 in Dec 2020
Technical
-well supported by ema200
-fluctuating around ema20
Factors to consider
-fundamental is solid but debt is too high for me
-good technical trend
-earning report that can always surprised the market in a good way
-current US recession period
So, is it a buy for you? [serious]
@Daily_Discussion@TigerPM@TigerStars@CaptainTiger
Comments